Skip to main content

Regenerating islet-derived 3-alpha serum

Test Code: 30146
Expand All Collapse All
Clinical and Procedure
Clinical Utility

REG3α, a member of the third subclass of the Reg family, has been found in a variety of tissues but is not detected in immune cells. Studies have determined that REG3α expression is regulated by injury, infection, inflammatory stimuli, and pro-cytokines via different signaling pathways, and it acts as a tissue-repair, bactericidal, and anti-inflammatory molecule in human diseases.

REG3α has been found in a variety of tissues including the pancreas, small intestine, liver, skin, and gastrointestinal tract. It is constitutively expressed in the intestine, however, REG3α has been detected at low levels in healthy tissues (including the pancreas and skin) and has been shown to be highly expressed in tissue injury. Emerging evidence has demonstrated the differential expression of REG3α in patients with diabetes, inflammatory bowel disease (IBD), and cancers, which suggests an important physiological function of REG3α.

In human IBD colonic mucosa, HIP/PAP (REG3A) mRNA was demonstrated to be overexpressed and may play a role in colon mucosal regeneration. Similarly, REG3α gene expression is upregulated in the inflamed gastrointestinal (GI) mucosa and predominantly expressed in the lower GI tract.

This assay is recommended for the quantitative measurement of REG3α.

This individual assay has not been optimized for use in calculating the MAGIC Algorithm Probability (MAP) for aGVHD and will provide inaccurate values if used in calculating the MAGIC Algorithm Probability (MAP) for Hematopoietic Cell Transplant (HCT) patients.

See the Pre-Symptomatic, Symptomatic Onset, or Post-Treatment aGVHD assays here.


The assay for quantification of REG3α is a sandwich ELISA performed in a microtiter plate format. Conversion of a chromogenic substrate produces a color, the intensity of which is proportional to the concentration of REG3α in the sample material. A standard curve is used to calculate the concentration of REG3α in each of the test samples. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.


Specific to human REG3α.

Turnaround Time

3 business days from receipt of specimen

Specimen Information
Specimen Type Test Code CPT Code NY Approved Volume Assay Range Special Instructions
Serum (1) 30146 83520 Yes

1 mL

16.0-1,000.0 ng/mL

  • Whole blood should be collected in serum tube.
  • Allow to clot for 30 to 60 minutes and centrifuged to isolate the serum.
  • 1 mL of serum sample should be removed to a sterile tube and frozen immediately (-70°C).

The reference range for a healthy population is less than 74.5 ng/mL. However it should be noted that these ranges are obtained from a limited population of apparently healthy adults and are not diagnostic thresholds.


Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with the patient’s name and collection date. A Viracor Eurofins test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Eurofins Viracor, 18000 W 99th St. Ste, #10 Ste.#10, Lenexa, KS 66219.

Causes for Rejection

Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.


Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.



Wang, L., Quan, Y., Zhu, Y. et al. The regenerating protein 3A: a crucial molecular with dual roles in cancer. Mol Biol Rep 49, 1491–1500 (2022).

Lai YP, Li DQ, Li CW, Muehleisen B et al (2012) The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity 37:74–84.

Moniaus N, Song HY, Darnaud M, Garbin K et al (2011) Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers. Hepatology 53:618–627.

Zhang MY, Wang J, Guo J (2019) Role of regenerating islet-derived protein 3A in gastrointestinal cancer. Front Oncol 9:1449.

Zhang YW, Ding LS, Lai MD (2003) Reg gene family and human disease. World J Gastroenterol 9:2635–2641.

Orelle B, Keim V, Masciotra L, Dagorn JC, Iovanna JL (1992) Human pancreatitis-associated protein. Messenger RNA cloning and expression in pancreatic diseases. Comparative Study. J Clin Invest 90(6):2284–2291.

Tsuchida C, Tsuchida SS, Taked M (2017) Expression of REG family genes in human inflammatory bowel diseases and its regulation. Biochem Biophys Rep 12:198–205.

Edwards JA, Tan N, Toussaint N, Ou PQ et al (2020) Roles of regenerating islet-derived proteins in inflammatory bowel disease. World J Gastroenterol 26:2702–2714.

Ball LM, Egeler RM, EBMT Paediatric Working Party. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S58-64.

Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant. 1990 Jul;6(1):1-8.

Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant. 1990 Feb;5(2):69-82.

Paczesny S, Krijanovski OI, Bruan TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 8;113(2):273-8.

Harris AC, Ferrara JLM, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012 119:2960-2963.

Closa D, Motoo Y, lovanna JL. Pancreatitis-associated protein: From a lectin to an anti-inflammatory cytokine. World J Gastroenterol. 2007 13(2):170-174.

Gironella M, lovanna JL, Sans M, et al. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut. 2005 54:1244-1253.

Back to top